Long-term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)
- Hongsik Kim
- , Dong Wan Kim
- , Miso Kim
- , Youngjoo Lee
- , Hee Kyung Ahn
- , Jang Ho Cho
- , Il Hwan Kim
- , Yun Gyoo Lee
- , Seong Hoon Shin
- , Song Ee Park
- , Jiyoon Jung
- , Eun Joo Kang
- , Myung Ju Ahn*
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
55
Link opens in a new tab
Citations
(Scopus)